Induced Pluripotent Stem Cell Modeling in Parkinson's Disease

Induced pluripotent stem cells (iPSCs) have transformed Parkinson’s disease research by enabling the generation of patient-specific neurons that recapitulate key aspects of disease pathology in vitro. Reprogramming somatic cells into iPSCs permits the study of both familial and sporadic forms of Parkinson’s, capturing genetic mutations in SNCA, LRRK2, GBA and other risk genes within a human neuronal context. Differentiation protocols yield midbrain dopaminergic neurons, the principal cell type lost in patients, allowing investigation of α-synuclein aggregation, mitochondrial impairment, autophagic defects and neuroinflammatory responses. Three-dimensional cultures such as organoids and assembloids further advance model complexity by incorporating cell–cell interactions among neurons, astrocytes and microglia. Combined with multi-omics, machine learning and high-content imaging, iPSC models facilitate mechanistic dissection, precision stratification of disease subtypes and preclinical testing of neuroprotective compounds. This platform bridges basic science and translational efforts to identify therapeutic targets, develop patient-tailored interventions and ultimately mitigate the global burden of Parkinson’s disease.

Research from Nature Portfolio

Recent studies have applied machine learning to patient-derived iPSC neurons to classify mechanistic subtypes of Parkinson’s disease. By integrating multidimensional fluorescent labelling of organelles with deep neural networks, researchers achieved high-accuracy discrimination between control neurons and those bearing distinct disease signatures, highlighting the central roles of mitochondrial and lysosomal pathways. In parallel, transcriptomic, proteomic and metabolomic analyses of neural precursor cells and dopaminergic neurons from sporadic Parkinson’s patients revealed a reversible hypometabolic state driven by dysregulation of the α-ketoglutarate dehydrogenase complex. Importantly, modulation of aberrant Sonic Hedgehog signalling restored metabolic homeostasis, suggesting a novel neuroprotective strategy for early stages of disease.

Induced Pluripotent Stem Cell Modeling in Parkinson's Disease publication trend

The graph below shows the total number of articles in induced pluripotent stem cell modeling in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Induced pluripotent stem cell (iPSC): adult cell reprogrammed to an embryonic-like state capable of generating all cell types, including neurons.

Organoid: three-dimensional, multicellular structure derived from stem cells that mimics the architecture and function of an organ.

Dopaminergic neuron: nerve cell that synthesises and releases dopamine, the primary cell type lost in Parkinson’s disease.

α-Synuclein: neuronal protein that aggregates to form Lewy bodies, a hallmark of Parkinson’s pathology.

Mitochondrial dysfunction: impairment in the energy-generating organelles within the cell, contributing to neuronal degeneration.

Hypometabolism: reduced metabolic activity, often reflecting impaired mitochondrial or cellular function.

Single-cell RNA sequencing: technique for profiling gene expression in individual cells, enabling the study of cellular heterogeneity.

Organellar profiling: quantitative analysis of subcellular structures, such as mitochondria and lysosomes, to assess cellular health and disease states.

References

1. Prediction of mechanistic subtypes of Parkinson’s using patient-derived stem cell models. Nature Machine Intelligence (2023).
2. A reversible state of hypometabolism in a human cellular model of sporadic Parkinson’s disease. Nature Communications (2023).
3. Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids. npj Parkinson's Disease (2023).
4. Modeling Parkinson’s disease in midbrain-like organoids. npj Parkinson's Disease (2019).